摘要 |
Compounds of Formula (I): wherein: A represents bond, C<SUB>1-6</SUB>alkyl or CH-CH-C<SUB>1-4</SUB>alkyl; B represents bond, 0, S, SO, SO<SUB>2</SUB>, CO, CR<SUP>7</SUP>R<SUP>8</SUP>, CO<SUB>2</SUB>R<SUP>14</SUP>, CONR<SUP>14</SUP>R<SUP>15</SUP>, N(COR<SUP>14</SUP>)(COR<SUP>15</SUP>), N(SO<SUB>2</SUB>R<SUP>14</SUP>)(COR<SUP>15</SUP>) or NR<SUP>14</SUP>R<SUP>15</SUP>; D represents bond, or C<SUB>1-6</SUB>alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, SO, SO<SUB>2</SUB>, CO, CNR<SUP>5</SUP>, CNOR<SUP>5</SUP>, CNNR<SUP>5</SUP>R<SUP>6</SUP>, NR<SUP>11 </SUP>or CR<SUP>7</SUP>R<SUP>8</SUP>; Y represents CR<SUP>5</SUP>OR<SUP>11</SUP>, CR<SUP>5</SUP>SR<SUP>11</SUP>, NOR<SUP>5</SUP>, CR<SUP>5</SUP>NR<SUP>6</SUP>R<SUP>11</SUP>, SO, SO<SUB>2</SUB>, CO, CNR<SUP>5</SUP>, CNOR<SUP>5 </SUP>or CS; R<SUP>1 </SUP>and R<SUP>1'</SUP> each independently represents H, C<SUB>1-6</SUB>alkyl or C<SUB>1-4</SUB>alkylaryl; R<SUP>2 </SUP>represents CO<SUB>2</SUB>R<SUP>12</SUP>, CH<SUB>2</SUB>OR<SUP>12 </SUP>or CONR<SUP>12</SUP>R<SUP>13</SUP>, CONR<SUP>12</SUP>OR<SUP>13</SUP>, NR<SUP>12</SUP>COR<SUP>13</SUP>, SR<SUP>12</SUP>, PO(OH)<SUB>2</SUB>, PONHR<SUP>12 </SUP>or SONHR<SUP>12</SUP>; R<SUP>3 </SUP>represents H, C<SUB>1-6</SUB>alkyl or C<SUB>1-4</SUB>alkylaryl; R<SUP>4 </SUP>represents optionally substituted aryl or heteroaryl; Z represents a bond, CH<SUB>2</SUB>, O, S, SO, SO<SUB>2</SUB>, NR<SUP>5</SUP>, OCR<SUP>5</SUP>R<SUP>6</SUP>, CR<SUP>9</SUP>R<SUP>10</SUP>O or Z, R<SUP>4 </SUP>and Q together form an optionally substituted fused tricyclic group; R<SUP>5 </SUP>and R<SUP>6 </SUP>each independently represent H, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; R<SUP>7 </SUP>and R<SUP>8 </SUP>each independently represent H, halo, C<SUB>1-6 </SUB>alkyl or C<SUB>1-4 </SUB>alkylaryl; R<SUP>9 </SUP>and R<SUP>10 </SUP>each independently represents H, C<SUB>1-6 </SUB>alkyl optionally substituted by halo, cyano, OR<SUP>11 </SUP>or NR<SUP>6</SUP>R<SUP>11</SUP>, C<SUB>1-4 </SUB>alkylaryl optionally substituted by halo, cyano, OR11 or NR<SUP>6</SUP>R<SUP>11</SUP>, OR<SUP>11 </SUP>or, together with the N to which they are attached, R<SUP>9 </SUP>and R<SUP>10 </SUP>form a heterocyclic group: R<SUP>11 </SUP>represents H, C<SUB>1-6 </SUB>alkyl, C<SUB>1-4 </SUB>alkylaryl or COR<SUP>5</SUP>; R<SUP>12 </SUP>and R<SUP>13 </SUP>each independently represent H, C<SUB>1-3 </SUB>alkyl, C<SUB>1-3 </SUB>alkylaryl or C<SUB>1-3 </SUB>alkylheteroaryl or, together with the functionality to which they are attached, R<SUP>12 </SUP>and R<SUP>13 </SUP>form a heterocyclic group: R<SUP>14 </SUP>and R<SUP>15 </SUP>each independently represent H, C<SUB>1-6 </SUB>alkyl, C<SUB>1-4 </SUB>alkylaryl or C<SUB>1-4 </SUB>alkylheteroaryl or together with the functionality to which they are attached R<SUP>14 </SUP>and R<SUP>15 </SUP>form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs).
|